人參皂苷 Rg1作用機(jī)制 - Medchemexpress - MCE中國(guó)

1、Product Data SheetGinsenoside Rg1Cat. No.: HY-N0045CAS No.: 22427-39-0分式: CHO分量: 801.01作靶點(diǎn): Amyloid-; NF-B; Apoptosis作通路: Neuronal Signaling; NF-B; Apoptosis儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 100 mg/mL (124.84 mM)* means soluble, but saturation unk

2、nown.SolventMass1 mg 5 mg 10 mgConcentration制備儲(chǔ)備液1 mM 1.2484 mL 6.2421 mL 12.4842 mL5 mM 0.2497 mL 1.2484 mL 2.4968 mL10 mM 0.1248 mL 0.6242 mL 1.2484 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存式和期限：-80C, 6 months; -20C, 1 month。-80C 儲(chǔ)存時(shí)，請(qǐng)?jiān)?6 個(gè)內(nèi)使，-20C 儲(chǔ)存時(shí)，請(qǐng)?jiān)?1 個(gè)內(nèi)使。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥

3、式選擇適當(dāng)?shù)娜芙獍?。以下溶解案都?qǐng)先按照 In Vitro 式配制澄清的儲(chǔ)備液，再依次添加助溶劑：為保證實(shí)驗(yàn)結(jié)果的可靠性，澄 的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使； 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的式助溶1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (3.12 mM); Clear solution此案可獲得 2.5 mg/mL (3.12 mM，飽和度未知) 的澄清溶液

4、。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲(chǔ)備液加到 400 L PEG300 中，混合均勻；向上述體系中加50 L Tween-80，混合均勻；然后繼續(xù)加 450 L 理鹽定容 1 mL。2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (3.12 mM); Clear solutionPage 1 of 2 www.MedChemE此案可獲得 2.5 mg/mL (3.12 mM，飽和度未知) 的澄清溶液。以 1 mL 作液為例，取 100 L 25.0 mg/

5、mL 的澄 DMSO 儲(chǔ)備液加到 900 L 20% 的 SBE-CD 理鹽溶液中，混合均勻。3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (3.12 mM); Clear solution此案可獲得 2.5 mg/mL (3.12 mM，飽和度未知) 的澄 溶液，此案不適于實(shí)驗(yàn)周 期在半個(gè)以上的實(shí)驗(yàn)。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲(chǔ)備液加到 900 L 油中，混合均勻。BIOLOGICAL ACTIVITY物活性 Ginsenoside Rg1參的主 活性成分之。Ginseno

6、side Rg1 通過降低腦 A 平來發(fā)揮作。Ginsenoside Rg1減少 NF-B 核易位。IC & Target p65 A1-42體外研究 Ginsenoside Rg1 promotes the proliferation and differentiation of human dental pulp cells (hDPCs). The proliferativeability of hDPCs in Ginsenoside Rg1 is significantly enhanced (p0.05), especially in the Ginsenoside Rg1 (5

7、M)group. ALP activity and gene expressions of DSPP and DMP1 are increased in the induction group, Ginsenoside Rg1group, and their combination group compared with the control group (p0.05)3. In the RAW264.7 cells stimulatedby lipopolysaccharides (LPS) , the level of p-IB and p-p65 is significantly hi

8、gher than in controls and PPAR- levelsare significantly lower. Treatment with Rg1 vitro inhibits IB phosphorylation, reduces NF-B nuclear translocationand upregulates PPAR- expression2.體內(nèi)研究 In the inflamed joints of adjuvant-induced arthritis (AIA) rats, the level of p-IB and p-p65 is significantly

9、higher thanin controls and PPAR- levels are significantly lower. Treatment with Ginsenoside Rg1 in vivo inhibits IB phosphorylation, reduces NF-B nuclear translocation and upregulates PPAR- expression2. Ginsenoside Rg1 (G-Rg1) and Ginsenoside Rg2 (G-Rg2) reduce the escape latencies on the last two t

10、raining days compared to theAlzheimers disease (AD) model group (p0.05). In the spatial exploration test, the total time spent in the targetquadrant and the number of mice that exactly crossed the previous position of the platform are clearly shorter andlower, respectively, in the AD model group mic

11、e than in the normal control group mice (p0.01), a trend that isreversed by treatment with Ginsenoside Rg1 and Ginsenoside Rg2 (Ginsenoside Rg1, p0.01; Ginsenoside Rg2,p0.05). Treatment with Ginsenoside Rg1 and Ginsenoside Rg2 effectively improve cognitive function of the mice thathave declined due

12、to AD. Ginsenoside Rg1 and Ginsenoside Rg2 reduce A1-42 accumulation in APP/PS1 mice. In theGinsenoside Rg1 and Ginsenoside Rg2 treated mice, the pathological abnormalities observed in the APP/PS1 mice aregradually ameliorated. Clear nucleoli and light brown, sparsely scattered A deposits are visibl

13、e1.PROTOCOLCell Assay 3 hDPCs are incubated with different concentrations of Ginsenoside Rg1 (0.1, 0.5, 2.5, 5, 10 and 20 M) . The effectsof Ginsenoside Rg1 on the proliferative ability of hDPCs are evaluated by a fibroblast colony forming test, MTT assayand flow cytometry for cell cycle. The contro

14、l group, osteogenic induction group, Ginsenoside Rg1 (5 M) group andcombination group are designed, and alkaline phosphatase (ALP) activity and FQ-PCR for gene expressions ofdentine sialophosphoprotein (DSPP) and dentine matrix protein 1 (DMP1) are performed to evaluate thedifferentiation of hDPCs3.

15、MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice1Page 2 of 3 www.MedChemEAdministration 1 Male APP/PS1 mice, weighing 202 g, and male C57BL/6J mice, weighing 202 g, are used. The animals aremaintained in an air-conditioned animal center at 23

16、2C and a relative humidity of 5010%, with a natural light-dark cycle. Food and water are available ad libitum. After acclimatization for 1 wk, the mice are divided into fourgroups (n=10 in each group): the normal control group, the AD model group, the Ginsenoside Rg1 group, and theGinsenoside Rg2 gr

17、oup. According to the concentration-response curves, the mice in the Ginsenoside Rg1 andGinsenoside Rg2 groups are injected intraperitoneally once daily with Ginsenoside Rg1 and Ginsenoside Rg2 (30mg/kg), respectively, dissolved in saline. The mice in the AD model group (APP/PS1 mice) and the normal

18、 controlgroup (C57BL/6J nontransgenic littermates) are treated with isodose saline (0.9% w/v). All mice are treated for 1 mobefore brain metabolite profiling.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Li N, et al. A UPLC/MS-based metabolomics investigation of the protective effect of ginsenosides Rg1 and Rg2 in mice wit